Therefore, radiotherapy combined with CD47/SIRPα axis-associated immunotherapy can further promote anti-tumor efficiency, which is mainly associated with reshaped immune-activated irradiated tumor microenvironments (Table 2). The gene discussed is SIRPA; the disease is neoplasm.